Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_assertion type Assertion NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_head.
- NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_assertion description "[FHIT underexpression was detected in 27% of carcinoma in situ and 41% of invasive carcinoma, which suggests that it could be useful in assessing those carcinoma in situ lesions (ductal, DCIS and lobular, LCIS).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_provenance.
- NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_assertion evidence source_evidence_literature NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_provenance.
- NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_assertion SIO_000772 17164758 NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_provenance.
- NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_assertion wasDerivedFrom lhgdn-20090331 NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_provenance.
- NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_assertion wasGeneratedBy ECO_0000203 NP205612.RAKOYqGNNuWsRFgutMAmnSC9Yxhz_RdLyciTOLpfRXPLs130_provenance.